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013.02.00Abstract Aim of the work: To detect the incidence of secondary antiphospholipid syndrome
(APS) among Systemic lupus erythematosus (SLE) patients with positive anti-DNA antibodies.
Patients and methods: We studied 342 SLE patients; Group I: anti-DNA positive SLE patients
(n= 208) and Group II: anti-DNA negative SLE patients (n= 134), with a female to male ratio of
9.39:1 and a mean age of 27.49 ± 7.94 years and disease duration of 5.74 ± 3.97 years. Full history
taking, thorough clinical examination, laboratory and relevant radiological investigations were per-
formed. Disease activity was assessed using systemic lupus erythematosus disease activity index
(SLEDAI). Anti-dsDNA tests were carried out by indirect Immunoﬂuorescence (IF) technique.
Anti cardiolipin antibodies (IgG and IgM) and Anti-b2 glycoprotein-I antibody of IgG and/or
IgM isotype were detected by ELISA.
Results: The clinical manifestations, disease activity and laboratory investigations of the SLE
patients varied according to the anti-DNA antibodies. Thirty-six patients (17.3%) had secondary
APS in those with positive anti-DNA antibodies while only16 (11.9%) had secondary APS in those
with negative anti-DNA antibodies, with no signiﬁcant differences between both groups.
Conclusion: Apparent higher incidence of secondary APS was detected in anti-DNA positive
SLE patients. The non signiﬁcant differences between both groups may suggest that anti-DNAmatology and Rehabilitation
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142 S.M Gamal et al.positivity cannot be considered as the only predictor of secondary APS and further studies may be
needed to detect other factors which may increase the incidence of APS in SLE patients.
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Antiphospholipid syndrome (APS) comprises clinical features
such as arterial or venous thromboses and the detection of
so-called antiphospholipid antibodies (aPL) as anticardiolipin
antibodies (aCL) or lupus anticoagulant (LA) [1]. Also
patients with systemic lupus erythematosus (SLE) may form
antibodies to a phospholipid-beta-2 glycoprotein I complex.
Beta-2-glycoprotein I normally has an anticoagulant effect
that is diminished by this antibody formation. This may ex-
plain why antiphospholipid antibodies are implicated in the
etiology of the arterial and venous thromboses [2]. APS may
be the most commonly acquired hypercoagulable state, occur-
ring in up to 2% of the general population [1]. It is found in
20–35% of patients with SLE. The clinical course of the
secondary syndrome is independent of the activity and severity
of lupus, but the presence of APS worsens the prognosis of
patients with lupus [3]. Antiphospholipid antibodies, like
antinuclear antibodies (ANA), may be present prior to the
diagnosis of SLE [2].
Antibodies to DNA (anti-DNA) occur in 50–70% of pa-
tients with SLE and are almost speciﬁc for this disease. They
are very rarely found in healthy people, in patients with other
diseases, or in the relatives of patients with SLE [4]. They are
considered a serological hallmark of SLE, which is a proto-
typic autoimmune disease characterized by the production of
antibodies to components of the cell nucleus (ANA) in associ-
ation with diverse clinical manifestations [5]. Among these
ANAs, anti-DNA antibodies serve as markers for diagnosis
and prognosis and play an important role in immunopatho-
genesis via the formation of immune complexes [6]. A number
of studies have shown that levels of anti-double stranded
(dsDNA) antibodies tend to rise during ﬂares of disease activ-
ity in SLE, particularly in lupus nephritis [7] and [8], even in
some cases increases in their titer have been used as a guide
to treat lupus patients with conventional therapy before ﬂares
are clinically apparent [9,10]. Moreover, a decrease in anti-
dsDNA antibody titers has been associated with a clinical re-
sponse to rituximab [11].
As lupus autoantibodies are correlated with the occurrence
of speciﬁc clinical symptoms [12], according to the autoanti-
body proﬁle of SLE patients, different sub-groups of SLE
can be identiﬁed [13]. The aim of this study is to investigate
if the presence of anti-DNA in Egyptian SLE patients is asso-
ciated with a signiﬁcant increase in the incidence of secondary
antiphospholipid syndrome.
2. Patients and methods
The study, descriptive and cross-sectional, included 342 Egyp-
tian SLE patients fulﬁlling the updated ACR revised criteria
for the classiﬁcation of SLE [14].
The patients were attending the Rheumatology department
of Cairo University Hospitals during 2011. They were groupedaccording to anti-DNA positivity into Group I including anti-
DNA positive patients and Group II the anti-DNA negative
patients. All the patients had the disease duration more than
6 months at study entry. Full history taking, thorough clinical
examination, laboratory and relevant radiological investiga-
tions were performed for all the patients. Disease activity
was assessed using the Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI). Antiphospholipid syndrome (APS)
was diagnosed using Sapporo classiﬁcation criteria [15].
The clinical manifestations are described based on the
SLEDAI items. For all patients, serological examinations were
made to discover the presence of:
(1) Anti-nuclear antibody and anti-ds DNA which were
carried out by indirect Immunoﬂuorescence (IIF)
technique.
(2) Anti cardiolipin antibodies (IgG and IgM), Anti Ro
(SSA), Anti La (SSB), and Anti-b2 glycoprotein-I anti-
body of IgG and/or IgM isotype which were detected
by ELISA.
The study has been approved by local ethics committee and
it conforms to the standards currently applied in Cairo Univer-
sity Teaching Hospitals.
Statistics: The data were coded and entered using the statis-
tical package SPSS version 15. The data were summarized using
descriptive statistics: mean ± standard deviation (±SD), or
frequencies (n) and percentages (%). Statistical differences
between groups were tested using Chi Square test (v2) for qual-
itative variables, Independent sample t-test and ANOVA
(analysis of variance) for quantitative normally distributed
variables and nonparametric Mann–Whitney test and Krus-
kal–Wallis test for not normally distributed quantitative vari-
ables. Correlations were done to test for linear relations
between variables. A probability value (p value) <0.05 was
considered statistically signiﬁcant.3. Results
In the current study the ANA and anti DNA were positive in
329 (96.2%) and 208 (60.8%) of our patients respectively, Anti
Ro was found to be positive in 149 patients (43.6%), Anti La
in 53 patients (15.5%), while 56 patients (16.4%) showed posi-
tive antiphospholipid antibodies.
The SLE patients were divided according to the anti-DNA
positivity into two groups; Group I: anti-DNA positive SLE
patients (n= 208) and Group II: anti-DNA negative SLE pa-
tients (n= 134). The demographic features, disease activity
and laboratory data of both groups are shown in Tables 1–4,
respectively. There was no signiﬁcant difference in these
parameters according to DNA positivity except for SLE
patients with nephritis in whom these parameters were signiﬁ-
cantly higher in anti-DNA positive patients (Group I)
compared to those with negative anti-DNA (p= 0.000). Also,
Table 5 Comparison between presence of secondary anti-
phospholipid syndrome in both SLE groups with positive
(Group I) and negative (Group II) anti-DNA antibodies.
Group SLE patients (n= 342) no. (%) p Value
Group I (208)
ve APS 172 (82.7) 0.217
+ve APS 36 (17.3)
Group II (134)
ve APS 118 (88.1)
+ve APS 16 (11.9)
APS = antiphospholipid syndrome.
Table 1 Demographic characteristics of the SLE patients
(n= 342) with positive anti-DNA (Group I) and those with
negative anti-DNA (Group II).
Feature Group I
(n= 208)
Group I
(n= 134)
Sex male/female 172/36 118/16
Age (years) mean ± SD 26.71 ± 7.09 28.69 ± 9.01
Disease duration (Years) mean ± SD 5.58 ± 3.96 5.99 ± 3.99
Table 4 Laboratory data of SLE patients with positive
(Group I) and negative (Group II) anti-DNA antibodies.
Laboratory Investigation no. (%) Group I (208) Group II (134)
Hb (gm/dl) 11.16 ± 2.20 11.43 ± 1.82
WBC (dl) 8.10 ± 5.51 8.17 ± 6.21
PLT (dl) 280.42 ± 100.91 277.28 ± 83.86
ESR ﬁrst (mm/h) 63.54 ± 56.36 52.89 ± 38.63
24 h Urinary protein (g) 1.16 ± 1.18 0.69 ± 0.90
Hb = Hemoglobin, WBC=White blood cell count,
PLT= Platelet, ESR= Erythrocyte sedimentation rate.
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according to anti-DNA antibody positivity, however the urine
protein level was signiﬁcantly higher in Group I
(1.16 ± 1.18 g/24 h) compared to Group II SLE patients
(0.69 ± 0.90 g/24 h) (p= 0.000). Particular interest was
shown for the presence of secondary APS in SLE patients
according to the presence of positive anti-DNA antibodies;
36 patients (17.3%) had secondary APS in those with positive
anti-DNA antibodies while only 16 (11.9%) had secondary
APS in those with negative anti-DNA antibodies. However,
no signiﬁcant differences were found between anti-DNA anti-
bodies and the presence of secondary APS in both groups,
p=NS (Table 5).
4. Discussion
One of the most distinctive laboratory features of SLE is the
presence of autoantibodies to nuclear antigens including
dsDNA [16]. Antibodies to DNA are highly speciﬁc for SLE
and were reported to be found in 40–85% of the SLE patients
in one study [10] and in 50–70% in another [4]. This is in agree-
ment with the present results as the percentage of anti-DNA
positivity was 60.8%. The relation between anti-dsDNA with
lupus nephritis is documented in many studies [4,17,18], this
ﬁnding is in line with the signiﬁcant statistical difference found
in the current study between Group I (DNA positive) and
Group II (DNA negative) regarding lupus nephritis
(p= 0.000) and also the signiﬁcant statistical difference
regarding 24 h urinary protein between Group I and II
(p= 0.000).Table 2 Disease activity index of the SLE patients with positive (G
p Value Group II (n= 134) G
0.361 18.99 ± 9.93 1
SLEDAI = systemic lupus erythematosus disease activity index.
Table 3 Clinical manifestations of SLE patients with positive (Gro
Clinical manifestations no. (%) All patients (342)
Constitutional 194 (56.7)
Mucocutaneous 198 (57.9)
Arthritis 263 (76.9)
Renal 196 (57.3)
Neuropsychiatric 125 (36.5)
Pericarditis 58 (14.23)
Pleurisy 181 (52.9)Antiphospholipid antibodies are detected in approximately
1/3 of the SLE patients. High anticardiolipin antibody titers,
lupus anticoagulant and especially anti-beta2 glycoprotein I
antibodies are important predictors of APS [19]. The aPL pre-
dict early damage in patients with SLE disease and add to its
burden [20], including the renal involvement [21]. Loizou et
al. [22] found that raised levels of aCL were associated with
lupus nephritis (LN) but were unable to show an association
with anti-b2-glycoprotein I and did not look for the presence
of Lupus anticoagulant (LA). Moreover, they found that the
presence of aCL in conjunction with raised levels of anti-
dsDNA and anti-C1q antibodies is highly speciﬁc for LN
[16]. Alba et al. found that only the presence of LA was a sig-
niﬁcantly independent factor for the development of nephritis.roup I) and negative (Group II) anti-DNA antibodies.
roup I (n= 208) Disease activity mean ± SD
7.76 ± 9.12 SLEDAI
up I) and negative (Group II) anti-DNA antibodies.
Group I (208) Group II (134)
118 (56.7) 76 (56.7)
113 (54.3) 85 (63.4)
160 (76.9) 103(76.9)
165 (79.3) 31 (23.1)
70 (33.7) 55 (41.0)
36 (17.3) 22 (16.4)
107(51.4) 74 (55.2)
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features, in particular, a predisposition to venous and arterial
thrombotic vascular disorders in multiple organ systems. The
thrombotic effects may also extend to the renal circulation,
resulting in renal thrombotic microangiopathy or renal artery
stenosis [23].
The link between Anti DNA positivity and lupus nephritis,
and the association between the Anti DNA positivity and SLE
severity encouraged us in this study to investigate if this posi-
tivity was associated with increased incidence of secondary
APS in Egyptian SLE patients. Our results showed that APS
was found in 15.2% of our patients, which is not far away
from what was reported by Amigo and Khamashta 2000 [3],
with a higher incidence in the DNA positive group (17.3%)
compared to the negative group (11.9%), however the differ-
ence between the two groups was statistically non signiﬁcant.
The higher incidence of secondary APS detected in anti-
DNA positive SLE patients in this study is in line with what
was noted regarding the impact of anti-dsDNA as a useful tool
for the diagnosis and the prognosis of SLE [24], however the
non signiﬁcant difference between the two groups in the pres-
ent study may suggest that although DNA may be associated
with a higher incidence of secondary APS, it cannot be consid-
ered as the main predictor of APS in SLE patients.
In conclusion, an apparently higher incidence of secondary
APS was detected in anti-DNA positive SLE patients. The non
signiﬁcant differences between both groups may suggest that
Anti-DNA positivity cannot be considered as the only predic-
tor of secondary APS and further studies may be needed to de-
tect other factors which may increase the incidence of APS in
SLE patients. Further studies including a higher number of pa-
tients will be needed to study impact of anti DNA and other
lupus parameters as predictor of secondary APS in SLE.
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